Syngene International Limited (SYNGENE)
Investor Presentation
AI summary
- Q1 FY27 revenue from operations Rs 736 Cr, down 16% y-y; operating EBITDA margin 12% vs 24% in Q1 FY26
- PAT before exceptional items Rs 1 Cr; after exceptional items Rs -9 Cr
- Performance impacted by lack of offtake from major LMCDMO client and forex hedge loss
- Expect single-digit revenue degrowth for full FY27 with EBITDA margins in mid-20s
- Siddharth Mittal appointed MD & CEO from July 1, 2026
- Signed MoU with BRIC-THSTI for clinical development and translational research
- Advanced AI capabilities in drug discovery with gigascale virtual screening and de novo design
- Featured in TIME Magazine and Statista's World's Most Sustainable Companies 2026 ranking
- FY26 revenue Rs 3,739 Cr (+3% y-y); EBITDA margin 26%; PAT before exceptional items Rs 380 Cr
- Net cash position Rs 1,541 Cr as of June 30, 2026
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SYNGENE — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SYNGENE to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Syngene International Limited
Important.
The summary above is generated automatically from Syngene International Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.